{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:55:40Z","timestamp":1781456140468,"version":"3.54.1"},"reference-count":142,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":144,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hepatocellular carcinoma (HCC) remains a major driver of global cancer mortality, with HCC incidence projected to rise in the coming decades and chronic hepatitis B virus (HBV) continuing to account for a substantial proportion of cases worldwide. HBV-related HCC is distinguished by dual carcinogenic pathways: direct oncogenic effects mediated by viral persistence and genomic integration, and indirect carcinogenesis arising from chronic inflammation, fibrosis, and cirrhosis. Despite the success of nucleos(t)ide analogue (NA) therapy in suppressing HBV replication and reducing HCC incidence, residual risk persists, mandating risk-stratified surveillance even during long-term viral suppression. In parallel, advances in systemic therapy, particularly immune checkpoint inhibitor (ICI)-based combinations, have established immunotherapy-based regimens as preferred first-line options for unresectable disease. Emerging data have suggested a possible role for ICIs for select patients in earlier lines of disease, including the perioperative setting or in combination with transarterial chemoembolization for patients with intermediate-stage disease. This review synthesizes clinically relevant advances across the HBV-HCC continuum: molecular pathogenesis and risk stratification tools, antiviral strategies spanning curative and palliative settings, contemporary locoregional modalities, systemic regimens including ICI-based combinations, tyrosine kinase inhibitors, and biomarker-directed agents, and special clinical scenarios, such as portal vein tumor thrombus, high viral load, pregnancy, and viral coinfections. We emphasize HBV-specific safety considerations, including rigorous mitigation of reactivation risk with NA prophylaxis and standardized HBV DNA monitoring, and highlight future directions, such as validated composite biomarkers (e.g. circulating tumor DNA-based minimal residual disease assays), optimization of immuno-oncology locoregional therapy sequencing, and the potential influence of next-generation functional-cure HBV therapeutics on long-term HCC incidence and recurrence.<\/jats:p>","DOI":"10.1093\/gastro\/goag060","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:41:45Z","timestamp":1779968505000},"source":"Crossref","is-referenced-by-count":0,"title":["Current advances and future directions in the management of HBV-related hepatocellular carcinoma"],"prefix":"10.1093","volume":"14","author":[{"given":"Andrew F","family":"Ibrahim","sequence":"first","affiliation":[{"name":"School of Medicine, Texas Tech University Health Sciences Center , 3601 4th Street, Lubbock, TX 79430,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Sang","sequence":"additional","affiliation":[{"name":"School of Medicine, Texas Tech University Health Sciences Center , 3601 4th Street, Lubbock, TX 79430,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pojsakorn","family":"Danpanichkul","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Texas Tech University Health Sciences Center, 3601 4th Street, Lubbock, TX 79430, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwanjit","family":"Duangsonk","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Faculty of Medicine, Chiang Mai University, 110 Inthawarorot Road, Sri Phum, Mueang Chiang Mai, Chiang Mai 50200, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-9825","authenticated-orcid":false,"given":"Ju Dong","family":"Yang","sequence":"additional","affiliation":[{"name":"Karsh Division of Gastroenterology and Hepatology, Comprehensive Transplant Center, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A","family":"Kerr","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit G","family":"Singal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"2026061312344654000_goag060-B1","doi-asserted-by":"crossref","first-page":"e70245","DOI":"10.1002\/cncr.70245","article-title":"Gastrointestinal cancer statistics in 2022 and projection to 2050: GLOBOCAN estimates across 185 countries","volume":"132","author":"Danpanichkul","year":"2026","journal-title":"Cancer"},{"key":"2026061312344654000_goag060-B2","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(25)01635-6","article-title":"The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","author":"Collaborators GBDC","year":"2025","journal-title":"Lancet"},{"key":"2026061312344654000_goag060-B3","doi-asserted-by":"crossref","first-page":"e001231","DOI":"10.1136\/bmjgast-2023-001231","article-title":"Impact of the COVID-19 pandemic on patients with hepatocellular carcinoma in the West of Scotland: a cohort study","volume":"10","author":"McLaren","year":"2023","journal-title":"BMJ Open Gastroenterol"},{"key":"2026061312344654000_goag060-B4","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.3390\/cancers17101660","article-title":"Effects of the COVID-19 pandemic and post-pandemic changes on the diagnosis, treatment, and mortality of hepatocellular carcinoma in a tertiary center in Western Romania","volume":"17","author":"Burciu","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026061312344654000_goag060-B5","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2025.10.012","article-title":"Recent trends of incidence, mortality, treatment, and overall survival of hepatocellular carcinoma in the United States","author":"Lee","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061312344654000_goag060-B6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/gutjnl-2024-333227","article-title":"Epidemiology of gastrointestinal cancers: a systematic analysis from the Global Burden of Disease Study 2021","volume":"74","author":"Danpanichkul","year":"2024","journal-title":"Gut"},{"key":"2026061312344654000_goag060-B7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2147\/JHC.S307962","article-title":"The mechanisms of HBV-induced hepatocellular carcinoma","volume":"8","author":"Jiang","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"2026061312344654000_goag060-B8","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2026061312344654000_goag060-B9","doi-asserted-by":"crossref","first-page":"101571","DOI":"10.1016\/j.jhepr.2025.101571","article-title":"Hepatocellular carcinoma: epidemiology, diagnosis and treatment","volume":"7","author":"Mauro","year":"2025","journal-title":"JHEP Rep"},{"key":"2026061312344654000_goag060-B10","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1097\/HEP.0000000000001260","article-title":"Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021","volume":"82","author":"Danpanichkul","year":"2025","journal-title":"Hepatology"},{"key":"2026061312344654000_goag060-B11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jhep.2021.02.029","article-title":"Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan","volume":"75","author":"Liao","year":"2021","journal-title":"J Hepatol"},{"key":"2026061312344654000_goag060-B12","doi-asserted-by":"crossref","first-page":"e1001774","DOI":"10.1371\/journal.pmed.1001774","article-title":"Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial","volume":"11","author":"Qu","year":"2014","journal-title":"PLoS Med"},{"key":"2026061312344654000_goag060-B13","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","article-title":"Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment","volume":"31","author":"Hwang","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"2026061312344654000_goag060-B14","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.3390\/jcm13226770","article-title":"Beyond the liver: a comprehensive review of strategies to prevent hepatocellular carcinoma","volume":"13","author":"Polpichai","year":"2024","journal-title":"J Clin Med"},{"key":"2026061312344654000_goag060-B15","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of HBV-induced hepatocellular carcinoma","volume":"64","author":"Levrero","year":"2016","journal-title":"J Hepatol"},{"key":"2026061312344654000_goag060-B16","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"2026061312344654000_goag060-B17","doi-asserted-by":"crossref","first-page":"6910","DOI":"10.1038\/s41467-021-26805-8","article-title":"Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture","volume":"12","author":"\u00c1lvarez","year":"2021","journal-title":"Nat Commun"},{"key":"2026061312344654000_goag060-B18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"key":"2026061312344654000_goag060-B19","doi-asserted-by":"crossref","first-page":"7056","DOI":"10.3390\/ijms22137056","article-title":"Distinct patterns of HBV integration and TERT alterations between in tumor and non-tumor tissue in patients with hepatocellular carcinoma","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026061312344654000_goag060-B20","doi-asserted-by":"crossref","first-page":"12992","DOI":"10.1038\/ncomms12992","article-title":"Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma","volume":"7","author":"Zhao","year":"2016","journal-title":"Nat Commun"},{"key":"2026061312344654000_goag060-B21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/gutjnl-2020-323153","article-title":"Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma","volume":"71","author":"P\u00e9neau","year":"2022","journal-title":"Gut"},{"key":"2026061312344654000_goag060-B22","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/ng.2295","article-title":"Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma","volume":"44","author":"Sung","year":"2012","journal-title":"Nat Genet"},{"key":"2026061312344654000_goag060-B23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/hep.31231","article-title":"Hepatitis B virus\u2013telomerase reverse transcriptase promoter integration harnesses Host ELF4, resulting in telomerase reverse transcriptase gene transcription in hepatocellular carcinoma","volume":"73","author":"Sze","year":"2021","journal-title":"Hepatology"},{"key":"2026061312344654000_goag060-B24","doi-asserted-by":"crossref","first-page":"54253","DOI":"10.18632\/oncotarget.9801","article-title":"Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma","volume":"7","author":"Pezzuto","year":"2016","journal-title":"Oncotarget"},{"key":"2026061312344654000_goag060-B25","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1002\/hep.30571","article-title":"The antiresection activity of the X protein encoded by hepatitis Virus B","volume":"69","author":"Ren","year":"2019","journal-title":"Hepatology"},{"key":"2026061312344654000_goag060-B26","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1038\/s41388-018-0607-3","article-title":"Hepatitis B virus X protein promotes DNA damage propagation through disruption of liver polyploidization and enhances hepatocellular carcinoma initiation","volume":"38","author":"Ahodantin","year":"2019","journal-title":"Oncogene"},{"key":"2026061312344654000_goag060-B27","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.3389\/fimmu.2019.02048","article-title":"HBV-induced immune imbalance in the development of HCC","volume":"10","author":"Chen","year":"2019","journal-title":"Front Immunol"},{"key":"2026061312344654000_goag060-B28","doi-asserted-by":"crossref","first-page":"678537","DOI":"10.3389\/fmicb.2021.678537","article-title":"Persistence of hepatitis B virus infection: a multi-faceted player for hepatocarcinogenesis","volume":"12","author":"Ghosh","year":"2021","journal-title":"Front Microbiol"},{"key":"2026061312344654000_goag060-B29","doi-asserted-by":"crossref","first-page":"866","DOI":"10.4254\/wjh.v14.i5.866","article-title":"Role of hepatitis B virus in development of hepatocellular carcinoma: focus on covalently closed circular DNA","volume":"14","author":"Bianca","year":"2022","journal-title":"World J Hepatol"},{"key":"2026061312344654000_goag060-B30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","article-title":"Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection","volume":"58","author":"Hosaka","year":"2013","journal-title":"Hepatology"},{"key":"2026061312344654000_goag060-B31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jhep.2012.10.025","article-title":"Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis","volume":"58","author":"Kumada","year":"2013","journal-title":"J Hepatol"},{"key":"2026061312344654000_goag060-B32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.gastro.2014.03.048","article-title":"Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B\u2014A Nationwide Cohort Study","volume":"147","author":"Wu","year":"2014","journal-title":"Gastroenterology"},{"key":"2026061312344654000_goag060-B33","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/cncr.29159","article-title":"Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study","volume":"121","author":"Wang","year":"2015","journal-title":"Cancer"},{"key":"2026061312344654000_goag060-B34","doi-asserted-by":"crossref","first-page":"1585760","DOI":"10.3389\/fgstr.2025.1585760","article-title":"Impact of nucleos(t)ide analogues on the risk of hepatocellular carcinoma in chronic hepatitis B patients: a time-dependent Cox regression analysis","volume":"4","author":"Moriyama","year":"2025","journal-title":"Front Gastroenterol (Lausanne)"},{"key":"2026061312344654000_goag060-B35","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/hepr.14225","article-title":"The risk of developing hepatocellular carcinoma persists in chronic hepatitis B patients even after the long-term administration of nucleos(t)ide analogs","volume":"55","author":"Murai","year":"2025","journal-title":"Hepatol Res"},{"key":"2026061312344654000_goag060-B36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/hep.28916","article-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology"},{"key":"2026061312344654000_goag060-B37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.20517\/2394-5079.2022.51","article-title":"Risk of hepatocellular carcinoma development in long-term nucles(t)ide analog suppressed patients with chronic hepatitis B","volume":"9","author":"Fasano","year":"2023","journal-title":"Hepatoma Res"},{"key":"2026061312344654000_goag060-B38","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/jgh.15078","article-title":"Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review","volume":"35","author":"Tseng","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"key":"2026061312344654000_goag060-B39","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.cgh.2024.07.013","article-title":"Tenofovir is associated with a better prognosis than entecavir for hepatitis B virus\u2013related hepatocellular carcinoma","volume":"23","author":"Chung","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061312344654000_goag060-B40","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hep.31267","article-title":"Comparative effectiveness of entecavir versus Tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: a systematic review and meta-analysis","volume":"73","author":"Dave","year":"2021","journal-title":"Hepatology"},{"key":"2026061312344654000_goag060-B41","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cgh.2020.05.008","article-title":"Effects of Tenofovir vs Entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis","volume":"19","author":"Choi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061312344654000_goag060-B42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","article-title":"Tenofovir is associated with lower risk of hepatocellular carcinoma than Entecavir in patients with chronic HBV infection in China","volume":"158","author":"Yip","year":"2020","journal-title":"Gastroenterology"},{"key":"2026061312344654000_goag060-B43","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","article-title":"Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026061312344654000_goag060-B44","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.19407","article-title":"Risk of hepatocellular carcinoma with tenofovir vs entecavir treatment for chronic hepatitis B virus","volume":"5","author":"Tan","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026061312344654000_goag060-B45","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jhep.2025.05.028","article-title":"Attenuation of the second peak of bimodal recurrence of HBV-related HCC after curative treatment in the antiviral era","volume":"83","author":"Chan","year":"2025","journal-title":"J Hepatol"},{"key":"2026061312344654000_goag060-B46","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/2012.jama.11975","article-title":"Association between nucleoside analogues and risk of hepatitis B virus\u2013related hepatocellular carcinoma recurrence following liver resection","volume":"308","author":"Wu","year":"2012","journal-title":"Jama"},{"key":"2026061312344654000_goag060-B47","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/SLA.0000000000002727","article-title":"Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels","volume":"268","author":"Huang","year":"2018","journal-title":"Ann Surg"},{"key":"2026061312344654000_goag060-B48","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3748\/wjg.v29.i8.1243","article-title":"Predictors of early and late hepatocellular carcinoma recurrence","volume":"29","author":"Nevola","year":"2023","journal-title":"World J Gastroenterol"},{"key":"2026061312344654000_goag060-B49","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/1097-0142(20000801)89:3<500::AID-CNCR4>3.0.CO;2-O","article-title":"Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma","volume":"89","author":"Poon","year":"2000","journal-title":"Cancer"},{"key":"2026061312344654000_goag060-B50","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/hep.32241","article-title":"Risk of HBV reactivation during therapies for HCC: a systematic review","volume":"75","author":"Papatheodoridi","year":"2022","journal-title":"Hepatology"},{"key":"2026061312344654000_goag060-B51","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"2026061312344654000_goag060-B52","doi-asserted-by":"crossref","first-page":"goaf045","DOI":"10.1093\/gastro\/goaf045","article-title":"Current and new strategies for hepatocellular carcinoma surveillance","volume":"13","author":"Polpichai","year":"2025","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"2026061312344654000_goag060-B53","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","article-title":"Randomized controlled trial of screening for hepatocellular carcinoma","volume":"130","author":"Zhang","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026061312344654000_goag060-B54","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12885-021-08138-3","article-title":"PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma","volume":"21","author":"Feng","year":"2021","journal-title":"BMC Cancer"},{"key":"2026061312344654000_goag060-B55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/apt.14376","article-title":"Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection","volume":"47","author":"Mak","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026061312344654000_goag060-B56","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/apt.70403","article-title":"Meta-analysis: utilisation of hepatocellular carcinoma surveillance","volume":"63","author":"Tang","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"2026061312344654000_goag060-B57","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3350\/cmh.2019.0039","article-title":"Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard","volume":"26","author":"Esfeh","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"2026061312344654000_goag060-B58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2036.2009.04014.x","article-title":"Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis","volume":"30","author":"Singal","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2026061312344654000_goag060-B59","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40249-024-01225-0","article-title":"Disparities in hepatitis B virus healthcare service access among marginalised poor populations: a mixed-method systematic review","volume":"13","author":"Li","year":"2024","journal-title":"Infect Dis Poverty"},{"key":"2026061312344654000_goag060-B60","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC Staging Classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"2026061312344654000_goag060-B61","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1001\/archsurg.138.11.1207","article-title":"Perioperative and long-term outcome of major hepatic resection for small solitary hepatocellular carcinoma in patients with cirrhosis","volume":"138","author":"Lang","year":"2003","journal-title":"Arch Surg"},{"key":"2026061312344654000_goag060-B62","doi-asserted-by":"crossref","first-page":"e1541","DOI":"10.1634\/theoncologist.2019-0944","article-title":"Early and late recurrence of hepatitis B Virus-associated hepatocellular carcinoma","volume":"25","author":"Wang","year":"2020","journal-title":"Oncologist"},{"key":"2026061312344654000_goag060-B63","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ejso.2012.04.010","article-title":"High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study","volume":"38","author":"Yang","year":"2012","journal-title":"Eur J Surg Oncol"},{"key":"2026061312344654000_goag060-B64","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamasurg.2013.4648","article-title":"Prediction of hepatocellular carcinoma recurrence in patients with low hepatitis B virus DNA levels and high preoperative hepatitis B surface antigen levels","volume":"149","author":"Huang","year":"2014","journal-title":"JAMA Surg"},{"key":"2026061312344654000_goag060-B65","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2007.06.019","article-title":"Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma","volume":"47","author":"Sun","year":"2007","journal-title":"J Hepatol"},{"key":"2026061312344654000_goag060-B66","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"2026061312344654000_goag060-B67","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/00000658-200205000-00002","article-title":"New era of liver transplantation for hepatitis B: a 17-year single-center experience","volume":"235","author":"Anselmo","year":"2002","journal-title":"Ann Surg"},{"key":"2026061312344654000_goag060-B68","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1148\/radiol.2018171768","article-title":"radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma","volume":"287","author":"Lewandowski","year":"2018","journal-title":"Radiology"},{"key":"2026061312344654000_goag060-B69","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12885-023-10694-9","article-title":"TACE versus TACE\u2009+\u2009entecavir versus TACE\u2009+\u2009tenofovir in the treatment of HBV associated hepatocellular carcinoma","volume":"23","author":"Lu","year":"2023","journal-title":"BMC Cancer"},{"key":"2026061312344654000_goag060-B70","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jvir.2011.11.012","article-title":"Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues","volume":"23","author":"Toyoda","year":"2012","journal-title":"J Vasc Interv Radiol"},{"key":"2026061312344654000_goag060-B71","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1097\/HEP.0000000000001233","article-title":"Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: a randomized, open-label, phase 3 trial","volume":"82","author":"Ma","year":"2025","journal-title":"Hepatology"},{"key":"2026061312344654000_goag060-B72","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.2147\/JHC.S549670","article-title":"Adjuvant TACE improves prognosis after resection in dual-phenotype hepatocellular carcinoma: a propensity score-matched study","volume":"12","author":"Leng","year":"2025","journal-title":"J Hepatocell Carcinoma"},{"key":"2026061312344654000_goag060-B73","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"2026061312344654000_goag060-B74","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"2026061312344654000_goag060-B75","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.3390\/medicina61122164","article-title":"Navigating the therapeutic pathway and optimal first-line systemic therapy for hepatocellular carcinoma in the era of immune checkpoint inhibitors","volume":"61","author":"Shin","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"2026061312344654000_goag060-B76","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"2026061312344654000_goag060-B77","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"2026061312344654000_goag060-B78","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","article-title":"Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review","volume":"10","author":"Cappuyns","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026061312344654000_goag060-B79","doi-asserted-by":"crossref","first-page":"102633","DOI":"10.1016\/j.jceh.2025.102633","article-title":"Comparative efficacy and safety of first-line treatment with Atezolizumab\/Bevacizumab vs. Tyrosine-kinase Inhibitors in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"15","author":"Saowapa","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"2026061312344654000_goag060-B80","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jhep.2025.08.020","article-title":"Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab","volume":"84","author":"Kim","year":"2026","journal-title":"J Hepatol"},{"key":"2026061312344654000_goag060-B81","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00535-025-02308-x","article-title":"Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma","volume":"61","author":"Maesaka","year":"2026","journal-title":"J Gastroenterol"},{"key":"2026061312344654000_goag060-B82","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1002\/onco.13566","article-title":"FDA supplemental approval summary: lenvatinib for the treatment of unresectable hepatocellular carcinoma","volume":"26","author":"Nair","year":"2021","journal-title":"Oncologist"},{"key":"2026061312344654000_goag060-B83","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update","volume":"42","author":"Gordan","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026061312344654000_goag060-B84","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1158\/2767-9764.CRC-23-0072","article-title":"Salvage Ipilimumab plus Nivolumab after anti-PD-1\/PD-L1 therapy in advanced hepatocellular carcinoma","volume":"3","author":"Alden","year":"2023","journal-title":"Cancer Res Commun"},{"key":"2026061312344654000_goag060-B85","doi-asserted-by":"crossref","first-page":"1480520","DOI":"10.3389\/fimmu.2024.1480520","article-title":"The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients","volume":"15","author":"Ji","year":"2024","journal-title":"Front Immunol"},{"key":"2026061312344654000_goag060-B86","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/HEP.0000000000001026","article-title":"Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: the impact of successful antiviral treatment","volume":"81","author":"Celsa","year":"2025","journal-title":"Hepatology"},{"key":"2026061312344654000_goag060-B87","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s12876-025-04043-2","article-title":"Hepatocellular carcinoma patients with undetectable baseline hepatitis B viral DNA may benefit from immunotherapy","volume":"25","author":"Jian","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"2026061312344654000_goag060-B88","doi-asserted-by":"crossref","first-page":"jiag036; in press","DOI":"10.1093\/infdis\/jiag036","article-title":"Immune checkpoint inhibitor-induced rapid decline in HBV markers improves the prognosis of HBV-related hepatocellular carcinoma patients","author":"Ran","year":"2026","journal-title":"J Infect Dis"},{"key":"2026061312344654000_goag060-B89","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","article-title":"Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification","volume":"72","author":"Montironi","year":"2023","journal-title":"Gut"},{"key":"2026061312344654000_goag060-B90","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1200\/JCO.2022.40.4_suppl.379","article-title":"Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA","volume":"40","author":"Abou-Alfa","year":"2022","journal-title":"JCO"},{"key":"2026061312344654000_goag060-B91","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1053\/j.gastro.2023.02.042","article-title":"Disease etiology and outcomes after Atezolizumab Plus Bevacizumab in hepatocellular carcinoma: post-hoc analysis of IMbrave150","volume":"165","author":"Espinoza","year":"2023","journal-title":"Gastroenterology"},{"key":"2026061312344654000_goag060-B92","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"2026061312344654000_goag060-B93","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s10238-025-01851-4","article-title":"HBV reprograms the tumor microenvironment in hepatocellular carcinoma: mechanisms and therapeutic implications","volume":"26","author":"Shen","year":"2026","journal-title":"Clin Exp Med"},{"key":"2026061312344654000_goag060-B94","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40164-025-00642-7","article-title":"Hepatitis B surface antigen: carcinogenesis mechanisms and clinical implications in hepatocellular carcinoma","volume":"14","author":"Hao","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"2026061312344654000_goag060-B95","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.actbio.2025.04.042","article-title":"Immune-activated microspheres for enhanced chemoembolization of hepatocellular carcinoma by blocking the adenosine A2A receptor","volume":"199","author":"Chen","year":"2025","journal-title":"Acta Biomater"},{"key":"2026061312344654000_goag060-B96","doi-asserted-by":"crossref","first-page":"e003311","DOI":"10.1136\/jitc-2021-003311","article-title":"Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy","volume":"9","author":"Pinato","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026061312344654000_goag060-B97","doi-asserted-by":"crossref","first-page":"uxaf067","DOI":"10.1093\/cei\/uxaf067","article-title":"Post-transarterial chemoembolization hypoxia-induced HIF-1\u03b1\/WNT\/\u03b2-catenin signaling promotes hepatocellular carcinoma progression via programed death ligand 1 upregulation","volume":"219","author":"Ni","year":"2025","journal-title":"Clin Exp Immunol"},{"key":"2026061312344654000_goag060-B98","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2468-1253(24)00247-4","article-title":"Combination locoregional and systemic therapies in hepatocellular carcinoma","volume":"10","author":"Zhong","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026061312344654000_goag060-B99","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"2026061312344654000_goag060-B100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"key":"2026061312344654000_goag060-B101","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.annonc.2025.05.542","article-title":"TALENTACE: a phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC)","volume":"36","author":"Dong","year":"2025","journal-title":"Ann Oncol"},{"key":"2026061312344654000_goag060-B102","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"key":"2026061312344654000_goag060-B103","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026061312344654000_goag060-B104","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/S0140-6736(25)01720-9","article-title":"Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2\/3 trial","volume":"406","author":"Wang","year":"2025","journal-title":"Lancet"},{"key":"2026061312344654000_goag060-B105","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"2026061312344654000_goag060-B106","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"2026061312344654000_goag060-B107","first-page":"655","article-title":"Efficacy and safety of Atezolizumab plus Bevacizumab versus Sorafenib in hepatocellular carcinoma with main trunk and\/or contralateral portal vein invasion in IMbrave150","volume":"13","author":"Finn","year":"2024","journal-title":"Liver Cancer"},{"key":"2026061312344654000_goag060-B108","doi-asserted-by":"crossref","first-page":"409272","DOI":"10.1155\/2014\/409272","article-title":"The role of hypoxia inducible factor-1 in hepatocellular carcinoma","volume":"2014","author":"Luo","year":"2014","journal-title":"Biomed Res Int"},{"key":"2026061312344654000_goag060-B109","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.3390\/cancers17132110","article-title":"Efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"17","author":"Peng","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026061312344654000_goag060-B110","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","article-title":"Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial","volume":"64","author":"Lencioni","year":"2016","journal-title":"J Hepatol"},{"key":"2026061312344654000_goag060-B111","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"Meyer","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026061312344654000_goag060-B112","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update","volume":"84","author":"Reig","year":"2026","journal-title":"J Hepatol"},{"key":"2026061312344654000_goag060-B113","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jhep.2011.05.012","article-title":"Criteria for liver transplantation for HCC: what should the limits be?","volume":"55","author":"Silva","year":"2011","journal-title":"J Hepatol"},{"key":"2026061312344654000_goag060-B114","first-page":"211A","article-title":"Down-staging of hepatocellular carcinoma to within Milan criteria prior to liver transplantation: comparison of long-term outcome with tumors meeting Milan criteria without requiring down-staging: 40","volume":"56","author":"Yao","year":"2012","journal-title":"Hepatology"},{"key":"2026061312344654000_goag060-B115","doi-asserted-by":"crossref","first-page":"101287","DOI":"10.1016\/j.jceh.2023.09.008","article-title":"Managing HBV and HCV infection pre- and post-liver transplant","volume":"14","author":"Kumar","year":"2024","journal-title":"J Clin Exp Hepatol"},{"key":"2026061312344654000_goag060-B116","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jhep.2024.06.042","article-title":"Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: a systematic review and individual patient data meta-analysis","volume":"82","author":"Rezaee-Zavareh","year":"2025","journal-title":"J Hepatol"},{"key":"2026061312344654000_goag060-B117","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/HEP.0000000000001289","article-title":"Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: an international retrospective cohort study","volume":"82","author":"Moeckli","year":"2025","journal-title":"Hepatology"},{"key":"2026061312344654000_goag060-B118","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jhep.2026.01.006","article-title":"Updated data from IMbrave050: adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma","volume":"84","author":"Yopp","year":"2026","journal-title":"J Hepatol"},{"key":"2026061312344654000_goag060-B119","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jhep.2014.08.033","article-title":"Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management","volume":"61","author":"Chang","year":"2014","journal-title":"J Hepatol"},{"key":"2026061312344654000_goag060-B120","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jhep.2004.07.005","article-title":"Out of control: hepatitis B reactivation by transarterial treatment of hepatocellular carcinoma","volume":"41","author":"von Weizs\u00e4cker","year":"2004","journal-title":"J Hepatol"},{"key":"2026061312344654000_goag060-B121","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1478-3231.2010.02396.x","article-title":"The difficulties of managing severe hepatitis B virus reactivation","volume":"31","author":"Roche","year":"2011","journal-title":"Liver Int"},{"key":"2026061312344654000_goag060-B122","doi-asserted-by":"crossref","first-page":"111","DOI":"10.36401\/JIPO-23-28","article-title":"Management of hepatitis B virus and hepatitis C virus infections in patients with cancer receiving immune checkpoint inhibitors","volume":"7","author":"Mustafayev","year":"2024","journal-title":"J Immunother Precis Oncol"},{"key":"2026061312344654000_goag060-B123","doi-asserted-by":"crossref","first-page":"e245625","DOI":"10.1001\/jamanetworkopen.2024.5625","article-title":"Immune checkpoint inhibitor use during pregnancy and outcomes in pregnant individuals and newborns","volume":"7","author":"Gougis","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026061312344654000_goag060-B124","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12884-021-03612-z","article-title":"Tenofovir disoproxil fumarate in pregnancy for prevention of mother to child transmission of hepatitis B in a rural setting on the Thailand-Myanmar border: a cost-effectiveness analysis","volume":"21","author":"Bierhoff","year":"2021","journal-title":"BMC Pregnancy Childbirth"},{"key":"2026061312344654000_goag060-B125","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.2013.49.2678","article-title":"Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Loren","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026061312344654000_goag060-B126","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/cld.754","article-title":"Family counseling for hepatitis B and hepatitis C","volume":"13","author":"Kushner","year":"2019","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"2026061312344654000_goag060-B127","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/JCMA.0000000000000606","article-title":"Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: a meta-analysis","volume":"85","author":"Chang","year":"2022","journal-title":"J Chin Med Assoc"},{"key":"2026061312344654000_goag060-B128","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1053\/j.gastro.2025.07.037","article-title":"AGA clinical practice update on management of hepatitis delta: commentary","volume":"169","author":"Kushner","year":"2025","journal-title":"Gastroenterology"},{"key":"2026061312344654000_goag060-B129","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A Phase 3, randomized trial of Bulevirtide in chronic hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N Engl J Med"},{"key":"2026061312344654000_goag060-B130","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2025.04.028","article-title":"Hepatocellular carcinoma in people living with HIV","volume":"83","author":"Fulgenzi","year":"2025","journal-title":"J Hepatol"},{"key":"2026061312344654000_goag060-B131","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/gutjnl-2025-335456","article-title":"Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial","volume":"75","author":"Wu","year":"2025","journal-title":"Gut"},{"key":"2026061312344654000_goag060-B132","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s12072-021-10250-2","article-title":"Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial","volume":"15","author":"Meng","year":"2021","journal-title":"Hepatol Int"},{"key":"2026061312344654000_goag060-B133","doi-asserted-by":"crossref","first-page":"103046","DOI":"10.1016\/j.ctrv.2025.103046","article-title":"CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation","volume":"141","author":"Elahi","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"2026061312344654000_goag060-B134","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra2211764","article-title":"New approaches to chronic hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N Engl J Med"},{"key":"2026061312344654000_goag060-B135","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of Bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N Engl J Med"},{"key":"2026061312344654000_goag060-B136","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/v9040075","article-title":"HBV DNA integration: molecular mechanisms and clinical implications","volume":"9","author":"Tu","year":"2017","journal-title":"Viruses"},{"key":"2026061312344654000_goag060-B137","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2026061312344654000_goag060-B138","doi-asserted-by":"crossref","first-page":"1119744","DOI":"10.3389\/fonc.2023.1119744","article-title":"Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection","volume":"13","author":"Xu","year":"2023","journal-title":"Front Oncol"},{"key":"2026061312344654000_goag060-B139","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3390\/diagnostics13091537","article-title":"Persistently elevated HBV viral-host junction DNA in urine as a biomarker for hepatocellular carcinoma minimum residual disease and recurrence: a pilot study","volume":"13","author":"Lin","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"2026061312344654000_goag060-B140","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/hep.31230","article-title":"Cell-free virus-host chimera DNA from hepatitis B virus integration sites as a circulating biomarker of hepatocellular cancer","volume":"72","author":"Li","year":"2020","journal-title":"Hepatology"},{"key":"2026061312344654000_goag060-B141","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-3-540-69297-3_10","article-title":"Cancer prevention by vaccination against hepatitis B","volume":"181","author":"Chang","year":"2009","journal-title":"Recent Results Cancer Res"},{"key":"2026061312344654000_goag060-B142","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL clinical practice guidelines on the management of hepatitis B virus infection","volume":"83","author":"Cornberg","year":"2025","journal-title":"J Hepatol"}],"container-title":["Gastroenterology Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goag060\/68521691\/goag060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goag060\/68521691\/goag060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:10:03Z","timestamp":1781453403000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gastro\/article\/doi\/10.1093\/gastro\/goag060\/8707490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":142,"URL":"https:\/\/doi.org\/10.1093\/gastro\/goag060","relation":{},"ISSN":["2052-0034"],"issn-type":[{"value":"2052-0034","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,20]]},"article-number":"goag060"}}